The application of CDK1 inhibitors has been reported to improve the efficacy of the chemotherapeutic drug sorafenib targeting tumor stem cells in the treatment of hepatocellular carcinoma, anti-CDK1 combination chemotherapy significantly inhibits tumor growth in hepatocellular carcinoma, while being able to overcome resistance to sorafenib [59]. The gene discussed is CDK1; the disease is hepatocellular carcinoma.